VTR Stock Analysis: Ventas | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 47.150m USD | 12M Return: 38.1% | US92276F1003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 309M
Qual. Beats: 0
Rev. Trend: 98.4%
Qual. Beats: 8
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ventas, Inc. (NYSE: VTR) is a Chicago-based S&P 500 healthcare REIT founded in 1983 and publicly listed since 1998. The company owns and operates approximately 1,400 properties across North America and the United Kingdom, anchored by more than 850 senior housing communities and supplemented by outpatient medical buildings, research centers, and other healthcare facilities. Ventas combines an owned-property portfolio with senior housing operating platforms and uses its Ventas OI data platform to guide investment and operational decisions. As a healthcare REIT, Ventas primarily generates revenue through long-term triple-net leases, real estate ownership, and senior housing operations, and is required to distribute the majority of its taxable income to shareholders as dividends.
- Senior housing occupancy and rate growth expand NOI
- Interest rate hikes pressure cap rates and borrowing costs
- Aging population tailwinds drive sustained senior housing demand
| Net Income: 266.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.73 > 1.0 |
| NWC/Revenue: -18.46% < 20% (prev -1.10%; Δ -17.36% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.84b > Net Income 266.3m |
| Net Debt (13.2b) to EBITDA (2.50b): 5.30 < 3 |
| Current Ratio: 0.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (492.3m) vs 12m ago 7.23% < -2% |
| Gross Margin: -2.58% > 18% (prev 42.13%; Δ -44.71% > 0.5%) |
| Asset Turnover: 22.95% > 50% (prev 20.03%; Δ 2.92% > 0%) |
| Interest Coverage Ratio: 1.31 > 6 (EBIT TTM 1.01b / Interest Expense TTM 770.3m) |
| A: -0.04 (Total Current Assets 199.0m - Total Current Liabilities 1.39b) / Total Assets 29.7b |
| B: -0.27 (Retained Earnings -7.93b / Total Assets 29.7b) |
| C: 0.04 (EBIT TTM 1.01b / Avg Total Assets 28.1b) |
| D: 1.01 (Book Value of Equity 14.6b / Total Liabilities 14.4b) |
| Altman-Z'' = 0.17 = B |
As of August 06, 2026, the stock is trading at USD 92.53 with a total of 1,723,314 shares traded. Over the past week, the price has changed by -5.31%, over one month by +0.35%, over three months by +7.25% and over the past year by +38.08%.
Current recommended Stop Loss: 85.50 (which is 7.6% or 2.7 ATR below the current price).
Ventas has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy VTR.
- StrongBuy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 99.1 | 7% |
P/E Trailing = 180.2353
P/E Forward = 161.2903
P/S = 7.7133
P/B = 3.243
P/EG = 1.7166
Revenue TTM = 6.44b USD
EBIT TTM = 1.01b USD
EBITDA TTM = 2.50b USD
Long Term Debt = 13.0b USD (from longTermDebt, last fiscal year)
Short Term Debt = 65.0m USD (from shortLongTermDebt, two quarters ago)
Debt = 13.4b USD (from shortLongTermDebtTotal, last fiscal year) + Leases 207.7m
Net Debt = 13.2b USD (calculated: Debt 13.4b - CCE 199.0m)
Enterprise Value = 60.4b USD (47.1b + Debt 13.4b - CCE 199.0m)
Interest Coverage Ratio = 1.31 (Ebit TTM 1.01b / Interest Expense TTM 770.3m)
EV/FCF = 37.61x (Enterprise Value 60.4b / FCF TTM 1.61b)
FCF Yield = 2.66% (FCF TTM 1.61b / Enterprise Value 60.4b)
FCF Margin = 24.92% (FCF TTM 1.61b / Revenue TTM 6.44b)
Net Margin = 4.13% (Net Income TTM 266.3m / Revenue TTM 6.44b)
Gross Margin = -2.58% ((Revenue TTM 6.44b - Cost of Revenue TTM 6.61b) / Revenue TTM)
Gross Margin QoQ = 39.82% (prev 39.56%)
Tobins Q-Ratio = 2.04 (Enterprise Value 60.4b / Total Assets 29.7b)
Interest Expense / Debt = 5.74% (Interest Expense 770.3m / Debt 13.4b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 798.4m (EBIT 1.01b * (1 - 21.00%))
Current Ratio = 0.14 (Total Current Assets 199.0m / Total Current Liabilities 1.39b)
Debt / Equity = 0.92 (Debt 13.4b / totalStockholderEquity, last quarter 14.6b)
Debt / EBITDA = 5.30 (Net Debt 13.2b / EBITDA 2.50b)
Debt / FCF = 8.24 (Net Debt 13.2b / FCF TTM 1.61b)
Total Stockholder Equity = 13.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.95% (Net Income 266.3m / Total Assets 29.7b)
RoE = 2.02% (Net Income TTM 266.3m / Total Stockholder Equity 13.2b)
RoCE = 3.86% (EBIT 1.01b / Capital Employed (Equity 13.2b + L.T.Debt 13.0b))
RoIC = 2.84% (NOPAT 798.4m / Invested Capital 28.1b)
WACC = 5.05% (E(47.1b)/V(60.6b) * Re(5.20%) + D(13.4b)/V(60.6b) * Rd(5.74%) * (1-Tc(0.21)))
Discount Rate = 5.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.18 | Cagr: 8.80%
[DCF] Terminal Value 77.97% ; FCFF base≈1.46b ; Y1≈1.67b ; Y5≈2.46b
[DCF] Fair Price = 46.40 (EV 37.0b - Net Debt 13.2b = Equity 23.8b / Shares 512.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: 98.38 | Revenue CAGR: 14.69% | SUE: 1.91 | # QB: 8
EPS current Quarter (2026-09-30): EPS=0.15 | Chg30d=-28.57% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=-14.02% | Revisions=-25% | GrowthEPS=+1.9% | GrowthRev=+20.9%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=+84.1% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: -62% (up=0, down=5)